卡介苗膀胱灌注与2019冠状病毒病：施与还是不施？
Intravesical BCG amid COVID-19: To give or not to give?
作者信息
Desouky Elsayed
机构信息
Department of Urology, Wexham Park NHS Hospital, Berkshire, UK; Department of Urology, Alexandria Main University Hospital, Alexandria, Egypt.
出版信息
Turk J Urol. 2020 Jul;46(4):274-276. doi: 10.5152/tud.2020.20206.
During the coronavirus disease 2019 pandemic, there has been a reduction in the provision of all elective services. This poses enormous pressure on urologists as regards to patients with bladder cancer who need intravesical Bacille Calmette Guerin (BCG) treatment. The evolving situation of the pandemic mandates a pragmatic approach in clinical decisions; to date, there are no uniform consensus guidelines about how to manage these patients and the factors affecting our decision for service provision. These concerns need to be addressed not only for the current crisis but also for the upcoming next phase of the pandemic.
在2019年冠状病毒病大流行期间，所有择期服务的提供都有所减少。这给需要膀胱内灌注卡介苗（BCG）治疗的膀胱癌患者的泌尿外科医生带来了巨大压力。大流行的不断演变态势要求在临床决策中采取务实的方法；迄今为止，关于如何管理这些患者以及影响我们服务提供决策的因素，尚无统一的共识指南。这些问题不仅需要在当前危机中得到解决，也需要在即将到来的大流行下一阶段得到解决。
Zotero 插件